Bi-Specific MAbS Global Market Report 2025

Bispecific monoclonal antibodies (BsAbs) feature dual binding sites, strategically designed to target two distinct antigens or epitopes. Unsuch as traditional monoclonal antibodies (MoAbs), BsAbs offer diverse therapeutic applications, making them invaluable in treating various diseases and advancing tumor immunotherapy.

Prominent examples of bispecific monoclonal antibodies include catumaxomab (utilized for malignant ascites treatment), blinatumomab, duligotumab, and SAR 156597. Catumaxomab, a rat-mouse hybrid monoclonal antibody, addresses malignant ascites linked to metastasizing cancer. These innovative antibodies find application in both in vivo and in vitro settings, contributing to the treatment of conditions such as cancer, autoimmune diseases, inflammatory diseases, infectious diseases, and microbial diseases. Hospitals, research institutes, and other healthcare entities leverage bispecific monoclonal antibodies to enhance therapeutic interventions and advance medical research.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment-many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.

The bi-specific MAbs or bispecific monoclonal antibodies market research report is one of a series of new reports from The Business Research Company that provides bi-specific MAbs or bispecific monoclonal antibodies market statistics, including bi-specific MAbs or bispecific monoclonal antibodies industry global market size, regional shares, competitors with a bi-specific MAbs or bispecific monoclonal antibodies market share, detailed bi-specific MAbs or bispecific monoclonal antibodies market segments, market trends and opportunities, and any further data you may need to thrive in the bi-specific MAbs or bispecific monoclonal antibodies industry. This bi-specific MAbs or bispecific monoclonal antibodies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The bi-specific MAbS market size has grown rapidly in recent years. It will grow from $7.83 billion in 2024 to $9.05 billion in 2025 at a compound annual growth rate (CAGR) of 15.5%. The growth in the historic period can be attributed to increased healthcare expenditure, increased funding, and government initiatives.

The bi-specific MAbS market size is expected to see rapid growth in the next few years. It will grow to $14.89 billion in 2029 at a compound annual growth rate (CAGR) of 13.3%. The growth in the forecast period can be attributed to an increasing prevalence of cancer, an increasing aging population, and an increase in the prevalence of chronic diseases. Major trends in the forecast period include a focus on technological advancements, product innovation, a focus on artificial intelligence, investment in targeted and combination therapy, and strategic partnerships.

The forecast of 13.3% growth over the next five years reflects a modest reduction of 0.4% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. oncology research by inflating prices of bi-specific monoclonal antibodies developed in Switzerland and Japan, resulting in delayed cancer immunotherapy trials and higher precision medicine costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The anticipated rise in cancer and other chronic diseases is poised to significantly bolster the growth of the bispecific monoclonal antibodies (MAbs) market in the foreseeable future. Bispecific monoclonal antibodies are tailored for treating a spectrum of conditions including various cancers, infectious diseases, central nervous system disorders, and autoimmune disorders. Distinguished by their ability to target multiple tumor antigens, these antibodies are considered more efficacious than conventional monoclonal antibodies (moAbs) in impeding cancer progression. For instance, the American Cancer Society (ACS) projected an estimated 609,820 cancer-related deaths in the USA in 2023, accentuating the increasing need for bi-specific MAbs to effectively combat chronic diseases, notably cancer.

Government initiatives geared towards healthcare research and development are poised to propel the growth of the bispecific MAbs market. These initiatives encompass specific actions, policies, or programs undertaken by governmental bodies to address healthcare challenges, achieve defined objectives, or instigate positive societal changes. An illustrative example involves the collaboration between the Biomedical Advanced Research and Development Authority (BARDA), a division of the U.S. Department of Health and Human Services (HHS), and Regeneron Pharmaceuticals Inc., a US-based science and technology company. Their collaboration under the U.S. Department of Health and Human Services' 'Project NextGen' aims to develop a next-generation monoclonal antibody therapy for preventing SARS-CoV-2 infection. BARDA's commitment to fund up to 70% of Regeneron's clinical development expenses for this therapy, amounting to an estimated contract value of approximately $326 million, exemplifies governmental support for healthcare research and development. Such initiatives drive advancements and contribute to the growth of the bispecific MAbs market.

Companies within the Bi-Specific MAbS market are increasingly engaging in strategic initiatives, particularly collaborations and partnerships, aimed at expanding their product portfolios and global reach. These collaborations represent cooperative ventures between multiple organizations to achieve shared objectives. For instance, in October 2022, Gilead Sciences, a US-based biopharmaceutical firm, partnered with MacroGenics, another US-based biopharmaceutical company, in an exclusive collaboration to develop MGD024, a bispecific antibody targeting CD123 and CD3. This initiative, utilizing MacroGenics' DART platform, includes two additional bispecific research programs. Gilead secured an exclusive option to license MGD024, designed to address various hematologic malignancies such as acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). MGD024's unique design aims to mitigate cytokine-release syndrome (CRS) and facilitate intermittent dosing, potentially enhancing treatment convenience and improving clinical outcomes for AML and MDS patients.

Major companies in the bispecific monoclonal antibodies (mAbs) market are concentrating on developing advanced bispecific antibody technology platforms to optimize the manufacturing process for complex antibody formats. A bispecific antibody technology platform is designed to produce antibodies that can bind to two distinct targets, ensuring accurate targeting and optimal functionality. This approach simplifies development and manufacturing, facilitating effective therapies for complex diseases. For instance, in January 2022, Lonza, a healthcare manufacturing organization based in Switzerland, launched the bYlok. This innovative solution aims to streamline and enhance the discovery and development of bispecific antibodies, which can simultaneously target two different antigens, making them highly effective for treating complex conditions such as oncology and autoimmune disorders. The platform is intended to expedite production, allowing for the faster development of these groundbreaking therapies and providing more effective treatment options.

In June 2024, Johnson & Johnson, a pharmaceutical company based in the US, acquired Proteologix, Inc. for $850 million. This strategic acquisition allows Johnson & Johnson to incorporate two promising bispecific antibodies, PX-128 and PX-130, which target key pathways involved in conditions such as atopic dermatitis and asthma. It enhances J&J's expertise in immunology while reinforcing its commitment to innovative care. The acquisition also grants access to additional bispecific antibody programs, improving treatment options for chronic conditions. Proteologix, Inc. is a US-based company dedicated to developing bispecific antibodies.

Major companies operating in the bi-specific MAbS market include F. Hoffmann-La Roche AG, Amgen Inc, Johnson & Johnson, Sino Biological Inc, Kyowa Kirin, Zai Lab, Alphamab Oncology, Celldex Therapeutics, Biocon, EpimAb Biotherapeutics, ABL Bio, Takeda pharmaceuticals, Innovent Biologics, Merck & Co Inc, Eli Lilly Company Inc., AbbVie Inc, Bayer AG, Pfizer Inc, Novartis AG, GlaxoSmithKline, AstraZeneca, Cytiva, Bristol Myers Squibb, AbCellera, BioMarin Pharmaceuticals, Parexel, Sanofi S.A., Novo Nordisk A/S, BBI Solutions, Aspen Pharmacare, Amoun Pharmaceuticals CO Ltd, Baxter International, Cipla Medpro South Africa

North America was the largest region in the bi-specific MAbs market in 2024. The regions covered in the bi-specific MAbs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the bi-specific MAbs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain

The bi-specific MAbs or bispecific monoclonal antibodies market consists of sales of trifunctional antibodies, chemically linked Fabs, and bispecific T cell engagers. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Bi-Specific MAbS Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on bi-specific mabs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for bi-specific mabs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The bi-specific mabs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Catumaxomab (Removab), Blinatumomab, Duligotumab, Emicizumab, Amivantamab, Faricimab, Teclistamab
• 2) By Product Type: In Vivo, In Vitro
• 3) By Indication: Cancer, Haemophilia A, Ophthalmic
• 4) By End Use: Hospitals, Research Institutes, Other End-Users
• Subsegments:
• 1) By Catumaxomab (Removab): Cancer Therapy; Targeting EpCAM and CD3
• 2) By Blinatumomab: Acute Lymphoblastic Leukemia (ALL) Treatment; Targeting CD19 and CD3
• 3) By Duligotumab: Oncology Treatments; Targeting Epidermal Growth Factor Receptor (EGFR)
• 4) By Emicizumab: Hemophilia A Treatment; Targeting Factor IXa and Factor X
• 5) By Amivantamab: Non-Small Cell Lung Cancer (NSCLC) Therapy; Targeting EGFR And MET
• 6) By Faricimab: Ophthalmology Treatment (Wet Age-related Macular Degeneration, Diabetic Macular Edema); Targeting Angiopoietin-2 And VEGF-A
• 7) By Teclistamab: Multiple Myeloma Treatment; Targeting BCMA and CD3
• Companies Mentioned: F. Hoffmann-La Roche AG; Amgen Inc; Johnson & Johnson; Sino Biological Inc; Kyowa Kirin; Zai Lab; Alphamab Oncology; Celldex Therapeutics; Biocon; EpimAb Biotherapeutics; ABL Bio; Takeda pharmaceuticals; Innovent Biologics; Merck & Co Inc; Eli Lilly Company Inc.; AbbVie Inc; Bayer AG; Pfizer Inc; Novartis AG; GlaxoSmithKline; AstraZeneca; Cytiva; Bristol Myers Squibb; AbCellera; BioMarin Pharmaceuticals; Parexel; Sanofi S.A.; Novo Nordisk A/S; BBI Solutions; Aspen Pharmacare; Amoun Pharmaceuticals CO Ltd; Baxter International; Cipla Medpro South Africa
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.